Low-dose growth hormone replacement lowers plasma leptin and fat stores without affecting body mass index in adults with growth hormone deficiency.

Florkowski CM, Collier GR, Zimmet PZ, Livesey JH, Espiner EA, Donald RA

Clinical endocrinology1 Dec 1996Cited by 54 (Europe PMC)

PMID9039344DOI10.1046/j.1365-2265.1996.830895.xPepBankPUB-09039344

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

01HumanRandomized controlled trialEfficacy outcome
In GH-deficient adults, body tissue fat was 30.1 +/- 2.2% after GH versus 31.9 +/- 2.2% after placebo (P < 0.001).
In plain wordsIn GH-deficient adults, body tissue fat was lower after GH than after placebo.
Peptide
HGH (somatotropin)
Outcome
DecreaseTotal body tissue fat
Study
n = 20
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
Up to 0.25 U/kg/week in daily doses · 3 monthsAs given in this study (human).
Measurements
Total body tissue fat
30.1%
after GH (+/- 2.2 SE)
Total body tissue fat
31.9%
after placebo (+/- 2.2 SE)
P value
< 0.001
GH vs placebo, ANOVA
Source sentences
Summary
Total body tissue fat (mean +/- SE) was 30.1 +/- 2.2% after GH compared with 31.9 +/- 2.2% after placebo, P < 0.001 (ANOVA).
1 context sentence(design, population, supporting numbers)
Summary · context
Twenty adults, mean age 47 years (range 20-69) with proven GH deficiency were randomly allocated to either GH (up to 0.25 U/kg/week in daily doses) or placebo for 3 months before cross-over to the opposite treatment.
Report a problemFND-0903934401
02HumanRandomized controlled trialEfficacy outcome
In GH-deficient adults, BMI did not change significantly: 29.1 +/- 1.3 after placebo versus 28.8 +/- 1.2 kg/m2 after GH.
In plain wordsIn GH-deficient adults, BMI did not change significantly with GH compared with placebo.
Peptide
HGH (somatotropin)
Outcome
No significant changeBMI
Study
n = 20
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
Up to 0.25 U/kg/week in daily doses · 3 monthsAs given in this study (human).
Measurements
BMI
28.8 kg/m2
after GH (+/- 1.2 SE)
BMI
29.1 kg/m2
after placebo (+/- 1.3 SE)
Source sentences
Summary
There were no significant changes in BMI (kg/m2), 29.1 +/- 1.3 after placebo vs 28.8 +/- 1.2 after GH; or waist to hip ratio (WHR), 0.91 +/- 0.01 after both placebo and GH.
1 context sentence(design, population, supporting numbers)
Summary · context
Twenty adults, mean age 47 years (range 20-69) with proven GH deficiency were randomly allocated to either GH (up to 0.25 U/kg/week in daily doses) or placebo for 3 months before cross-over to the opposite treatment.
Report a problemFND-0903934402
03HumanRandomized controlled trialEfficacy outcome
In GH-deficient adults, waist to hip ratio did not change significantly and was 0.91 +/- 0.01 after both GH and placebo.
In plain wordsIn GH-deficient adults, waist to hip ratio did not change significantly with GH compared with placebo.
Peptide
HGH (somatotropin)
Outcome
No significant changeWaist to hip ratio
Study
n = 20
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
Up to 0.25 U/kg/week in daily doses · 3 monthsAs given in this study (human).
Measurements
Waist to hip ratio
0.91 ratio
after GH (+/- 0.01 SE)
Waist to hip ratio
0.91 ratio
after placebo (+/- 0.01 SE)
Source sentences
Summary
There were no significant changes in BMI (kg/m2), 29.1 +/- 1.3 after placebo vs 28.8 +/- 1.2 after GH; or waist to hip ratio (WHR), 0.91 +/- 0.01 after both placebo and GH.
1 context sentence(design, population, supporting numbers)
Summary · context
Twenty adults, mean age 47 years (range 20-69) with proven GH deficiency were randomly allocated to either GH (up to 0.25 U/kg/week in daily doses) or placebo for 3 months before cross-over to the opposite treatment.
Report a problemFND-0903934403
04HumanRandomized controlled trialEfficacy outcome
In GH-deficient adults, plasma leptin adjusted for baseline body fat decreased linearly with time on GH compared with placebo (P = 0.03).
In plain wordsIn GH-deficient adults, adjusted plasma leptin decreased over time with GH compared with placebo.
Peptide
HGH (somatotropin)
Outcome
DecreaseAdjusted plasma leptin
Study
n = 20
Comparator
Placebo
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
Up to 0.25 U/kg/week in daily doses · 3 monthsAs given in this study (human).
Measurements
P value
0.03
adjusted plasma leptin, linear decrease with time on GH vs placebo, ANOVA
Source sentences
Summary
Plasma leptin (adjusted by using baseline percentage total body fat as a covariate) showed a significant linear decrease with time on GH compared with placebo (P = 0.03, ANOVA).
1 context sentence(design, population, supporting numbers)
Summary · context
Twenty adults, mean age 47 years (range 20-69) with proven GH deficiency were randomly allocated to either GH (up to 0.25 U/kg/week in daily doses) or placebo for 3 months before cross-over to the opposite treatment.
Report a problemFND-0903934404

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedNot applicableNCT00136032

Growth Hormone Administration and Its Effects on Cardiovascular Risk Factors in Growth Hormone Deficient Women

Massachusetts General Hospitaln = 63Jan 2002 to Nov 2006

Growth Hormone Deficiency

Trial page ClinicalTrials.govUpdated 18 Feb 2008

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:37 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.